Kylie Mason
Doctor
Medicine
Peter MacCallum Cancer Centre
Australia
Biography
Dr Kylie Mason is a Clinical Haematologist and translational researcher with a joint appointment at The University of Melbourne (NHMRC felowship). She leads the Late Effects and Survivorship stream within the VCCC, and has an interest in Adolescent and Young Adult (AYA) Haematology, with an honorary appointment at OnTrac - Youth Cancer Services.. Dr Mason has a research interest in lymphoma and CLL and is the lead investigator in a number of clinical trials. She also oversees the Sickle cell anaemia / Thalassaemia program at RMH / VCCC. Dr Mason is a member of the national PBAC economics subcommittee and the Clinical Oncology Society of Australasia (COSA) AYA executive committee.
Research Interest
LYMPHOMA, LEUKAEMIA, BENIGN HAEMATOLOGY INCLUDING SICKLE CELL DISEASE AND DISORDERS OF RED CELLS, ADOLESCENT AND YOUNG ADULT HAEMATOLOGY, SURVIVORSHIP AND LATE EFFECTS
Publications
-
Kylie D. Mason, Cassandra J. Vandenberg, Clare L. Scott, Andrew H. Wei, Suzanne Cory, David C.S. Huang, Andrew Roberts; In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proceedings of the National Academy of Science 2008; 105(46): 17961-6.
-
Mason KD, Carpinelli M, Fletcher J, Collinge J, Hilton A, Ellis S, Kelly P, Ekert P, Metcalf D, Roberts AW, Huang DCS, Kile BT ; Programmed anuclear cell death delimits platelet life span. Cell, 2007; 128, 1173-1186. (Impact factor 29.4) Cited as ‘Exceptional’ by Faculties of 1000 in Medicine and Biology.
-
Andrew J. Souers, Joel D. Leverson, Edwin R Boghaert, Scott L. Ackler, Nathanial D Catron, Jun Chen, Brian D. Dayton, Hong Ding, Sari L. Enschede, Wayne J. Fairbrother, David C.S. Huang, Sarah G. Hymowitz, Sha Jin, Seong Lin Khaw, Peter J. Kovar, Lloyd T Lam, Jackie Lee, Kennan C. Marsh, Heather L. Maecker, Kylie D. Mason, Michael J. Mitten, Paul M. Nimmer, Andrew Oleksijew, Chang H. Park, Cheol-Min Park, Darren C. Phillips, Andrew W Roberts, Deepak Sampath, John F. Seymour, Morey L. Smith, Gerard M. Sullivan, Stephen K. Tahir, Chris Tse, Michael D. Wendt, Yu Xiao, John C. Xue, Haichao Zhang, Rod A. Humerickhouse, Saul H. Rosenberg, Steven W. Elmore. Potent anti-tumor activity through selective inhibition of Bcl-2: ABT-199 induces apoptosis in Bcl-2-dependent malignancies while sparing platelets. Nature Medicine 2013; 9: 202–208
